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Ormaplatin resistance is associated with decreased accumulation of its
platinum (II) analogue, dichloro(D,L-trans)1,2-
diaminocyclohexaneplatinum(II)
D Rischin* and V Ling**
The Ontario Cancer Institute, Princess Margaret Hospital and Department ofMedical Biophysics, 500 Sherbourne Street, Toronto,
Ontario, Canada M4X 1K9.
Summary Ormaplatin (also known as tetraplatin) is a platinum-containing analogue which has recently
undergone clinical trials. Ormaplatin may undergo conversion to dichloro(D,L-trans)-1,2-diaminocyclohex-
aneplatinum(II) [PtCl2(trans-dach)]. The cisplatin-resistant murine lymphoma cell lines E8 and E5, were found
to be cross-resistant to ormaplatin and PtCl2(trans-dach). We found an inverse rank correlation between drug
resistance and drug accumulation for PtCl2(trans-dach) similar to our previous findings with cisplatin; however,
accumulation of ormaplatin in the resistant cells was increased. Ormaplatin cytotoxicity appears to result
primarily from extracellular conversion to PtCl2(trans-dach), since ormaplatin cytotoxicity was decreased under
conditions where extracellular conversion to PtCl2(trans-dach) was minimised. Co-incubation with different
inhibitors of energy metabolism resulted in a 65-70% increase in PtCl2(trans-dach) accumulation in the
parental cell line Ri.1 and a 113-307% increase in the resistant cell line E5 which suggests that the decrease in
accumulation in E5 may be at least partly energy dependent. We conclude from these findings that cross-
resistance to ormaplatin is associated with an energy-dependent decreased accumulation ofPtCl2(trans-dach) in
these cisplatin-resistant cell lines.
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Although cis-diamminedichloroplatinum(II) (cisplatin) has
significant activity against a broad range of human
malignancies, cisplatin-based chemotherapy is frequently not
curative. The development of resistance to cisplatin at a
cellular level is believed to be a major obstacle to improving
the outcome with cisplatin-based chemotherapy. Experimen-
tal models of cisplatin resistance have implicated multiple
mechanisms including decreased drug accumulation, elevated
glutathione and metallothionein levels, increased DNA repair
and increased tolerance of DNA damage (Andrews and
Howell, 1990; Shellard et al., 1993).
One approach to circumventing cisplatin resistance is the
development of platinum-containing analogues that are not
cross-resistant. Ormaplatin is one such analogue that was not
cross-resistant in the initial studies in L1210 and P388
leukaemias (Anderson et al., 1986; Wilkoff et al., 1987) or
in cisplatin-resistant human lung cancer cell lines (Ohmori et
al., 1993). Other studies have revealed that although
ormaplatin has a different pattern of sensitivity compared
with cisplatin or carboplatin, partial cross-resistance to
ormaplatin may occur (Hills et al., 1989; Perez et al., 1991;
Teicher et al., 1991; Bhuyan et al., 1991; Kelland et al., 1992).
The mechanisms of cross-resistance to ormaplatin have not
been extensively studied, but may be complex (Parker et al.,
1993). Ormaplatin has also been found to be less nephrotoxic
than cisplatin (Smith et al., 1988), but neurotoxicity has been
a significant problem in early clinical trials (Schilder et al.,
1994; O'Rourke et al., 1994).
Ormaplatin is a platinum (IV) compound which can be
reduced to the platinum (II) compound dichloro(D,L,-trans)-
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1,2 - diaminocyclohexaneplatinum (II) [PtCl2(trans - dach)]
(Eastman, 1987; Gibbons et al., 1989) (Figure 1). It has
been demonstrated that ormaplatin is converted to
PtCl2(trans-dach) in both tissue culture media and rat
plasma (Gibbons et al., 1989; Chaney et al., 1990). Although
it has been thought that this reduction could also occur
intracellularly (Eastman, 1987), recent work has revealed
unexpected intracellular biotransformation pathways for
ormaplatin which do not result in formation of PtCl2(trans-
dach) (Chaney et al., 1991).
Our laboratory has previously described a series of
cisplatin-resistant cell lines (E8 and E5) derived from the
murine lymphoma cell line, RI.1. In these cisplatin-resistant
cell lines there is an inverse rank correlation between the level
of resistance and intracellular drug accumulation (Kawai et
al., 1990). The mechanism of decreased accumulation in
cisplatin-resistant cell lines is poorly understood. It is also
unclear whether cisplatin or other platinum-containing
analogues cross the plasma membrane by passive diffusion
or by a mediated route. In this paper we demonstrate cross-
resistance to ormaplatin in these cell lines, which is associated
with decreased accumulation of PtCl2(trans-dach) but not
ormaplatin. The mechanism of decreased accumulation and
the factors affecting the reduction of ormaplatin to
PtCl2(trans-dach) were also investigated.
Materials and methods
Cell lines
The murine T cell lymphoma cell line Rl.1 and its cisplatin-
resistant variants, E8 and E5, have been described previously
(Kawai et al., 1990). These resistant cell lines were selected by
continuous exposure to cisplatin and exhibit decreased
accumulation of cisplatin. All cell lines were grown as
monolayers in RPMI 1640 medium (Gibco, Burlington,
Ontario, Canada) supplemented with 10% fetal bovine
serum (FBS) (Hyclone, Logan, Utah, USA), 100 units ml-'
penicillin and 100 jug ml-' streptomycin sulphate. All cell
cultures were incubated at 370C in a humidified atmosphere
containing 95% air and 5% carbon dioxide.Ormaplatin resistance
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Chemicals
Unlabelled and 3H-labelled ormaplatin and PtCl2(trans-dach)
were generous gifts from Dr R Haugwitz (Drug Synthesis
and Chemistry Branch, National Cancer Institute, Bethesda,
MD, USA). Clinical formulations of cisplatin and carbopla-
tin were obtained from Bristol Myers-Squibb (Belleville,
Ontario, Canada). Cystine and other components of RPMI-
medium were obtained from Gibco. Sodium azide, 2,4-
dinitrophenol and 5,5'-dithio-bis (2-nitrobenzoic acid) were
purchased from Sigma (St Louis, MO, USA). MTT was
purchased from ICN Biochemicals (Cleveland, OH, USA).
Phosphate-buffered saline (PBS) used in these experiments
contained: (in g 1-1) sodium chloride, 8; potassium chloride,
0.2; potassium hydrogen phosphate, 0.2; sodium hydrogen
phosphate, 1.15; calcium chloride hydrate, 0.132; magnesium
chloride hexahydrate, 0.1.
Drug resistance
The level of drug resistance was examined using the MTT
assay as previously described (Kawai et al., 1990; Carmichael
et al., 1987) with minor modifications. Briefly, cells (4000-
5000) seeded in microtitre plates were allowed to attach for
4 h and then exposed to drug for 1 or 96 h at 37°C. For the
1 h exposure assay, cells were exposed to drug, then medium
was aspirated and the wells washed twice with ice-cold PBS.
Cells were then incubated in fresh medium for 96 h. After
96 h MTT (50 MI of 2 mg ml-') was added to each well and
plates were incubated for another 4 h. Plates were
centrifuged, then wells were aspirated, 100 !l dimethyl
sulphoxide was added to each well and absorbance at a
wavelength of 540 nm measured. During the 96 h drug
exposures the medium was not changed, and the drug was
not washed out before the addition of MTT.
Drug accumulation
Cells were seeded in 60 mm tissue culture dishes 2 days
before examining drug accumulation. At the time of the
experiments cells were in exponential phase and approxi-
mately 50% confluent. Medium was aspirated and dishes
washed twice with prewarmed PBS before adding transport
buffer (phosphate-buffered saline with 11 mM glucose,
pH 7.3) containing radiolabelled drug. Incubations of less
than 10 min duration took place in a 37°C oven and for
longer incubations dishes were returned to the tissue culture
incubator (37°C, 5% carbon dioxide). Incubations were
terminated by rapidly aspirating buffer and washing three
times in ice-cold PBS. Cells were digested in 3 ml of 0.5 M
sodium hydroxide overnight. A 10 ,ul aliquot was taken for
duplicate protein estimation by the method of Bradford
modified for microtitre plate assay (Bradford, 1976; Simpson
and Sonne, 1982). A 1 ml aliquot was mixed with
scintillation fluid (ICN) and 50 pl glacial acetic acid and
counted on a Beckman LS-6000 scintillation counter using
the auto-d.p.m. setting. Surface binding was estimated by
incubating cells with drug for 15 s at 4°C. This value was
subtracted from all accumulation measurements. For
exposures of >30 min surface binding was <5% of the
total accumulation. For 5 min exposures surface binding
represented 15% and 25% of the total accumulation for R 1I
and E5 respectively. In experiments with metabolic inhibitors
cells were preincubated in PBS containing inhibitor but no
glucose for 5 min and then exposed to buffer without
glucose containing both radiolabelled PtCl2(trans-dach) and
the inhibitor for another 5 min. In efflux studies cells were
preloaded with [3H]PtCl2(trans-dach) for 15 min. Concentra-
tions of 2.5 gM for R1.1 and 3.75 guM for E5 were used to
give approximately equal intracellular drug accumulation.
Cells were then washed twice with ice-cold PBS and drug-
free buffer was added. Remaining intracellular drug
concentration was assessed over the next 30 min as
described above.
HPLC analysis of ormaplatin reduction
HPLC analysis of ormaplatin and PtCl2(trans-dach) was
performed with a 250 x 4.6 mm Zorbax 7 ODS column
(Phenomenex, Rancho Palos Verdes, CA, USA) using water
as the mobile phase at a flow rate of 0.5 ml min-m as
previously described (Anderson et al., 1986; Gibbons et al.,
1989). In the concentration range we were using PtCl2(trans-
dach) was not detectable with ultraviolet photometric
detection (HPLC-UV) as it has much lower absorptivity
than ormaplatin at 254 nm (Bhuyan et al., 1991). Therefore,
the decrease in the ormaplatin peak on HPLC-UV was
routinely used to estimate the percentage reduction of
ormaplatin. Simultaneous HPLC analysis using a radio-
chemical detector revealed that the combined ormaplatin and
PtCl2(trans-dach) peaks did not decrease under any of the
experimental conditions we employed which is consistent with
the decreases in the ormaplatin peak detected by HPLC-UV
being due to ormaplatin being converted to PtCl2(trans-dach).
[3H]PtCl2(trans-dach) (2.5 tM) was incubated in various
transport buffers in the presence or absence of cells for
30 min at 37°C in the tissue culture incubator. After this
incubation an aliquot of the buffer was centrifuged in an air-
driven ultracentrifuge (Beckman) for 15 s to remove any cells
or debris and then 50 pl was injected for HPLC analysis.
Extracellular thiol concentration
Sulfhydryl content was determined using a modification of
the Ellman method (Ellman, 1980). Cells were seeded in
100 mm tissue culture dishes two days before experiments at
which time they were in exponential phase. Cells were
incubated in 5 ml transport buffer with or without cystine
for 1 h at 37°C in the tissue culture incubator. After
incubation 1.5 ml of the buffer was removed and centrifuged
for 2 min at 2000 r.p.m. in a tabletop centrifuge to remove
any floating cells. An aliquot of 1.5 ml of the buffer was
mixed with 1.5 ml of 0.2 M potassium phosphate- 10 mM
EDTA, pH 8.0. Absorbance at 412 nm was measured, then
210 ,ul of 6 mM 5,5'-dithiobis (2-nitrobenzoic acid) was added
and the increase in absorbance was measured after 5 min.
The sulfhydryl content was calculated from the increase in
absorbance using cysteine as a standard.
Results
Drug resistance
In the 4 day continuous exposure assays there was partial
cross-resistance to ormaplatin but marked cross-resistance to
carboplatin, relative to the resistance to cisplatin (Table I).
The degree of cross-resistance to the d and 1 isomers of
ormaplatin was similar to the racemic mixture, though the 1
isomer was less potent than the d isomer. As expected based
on the known conversion of ormaplatin to PtCl2(trans-dach)
in tissue culture media (Gibbons et al., 1989), PtCl2(trans-
dach) gave very similar results to ormaplatin. In the 1 h
exposure assays the fold resistance to cisplatin was less than
in the 4 day assays, but the cross-resistance to ormaplatin
was greater in the 1 h assay particularly in E5. In a study of
cisplatin-resistant human ovarian cell lines, it was proposed
that there are two platinum-resistant phenotypes; one with
high levels of resistance to cisplatin and carboplatin and more
moderate resistance to ormaplatin, and the other with low
levels of resistance to cisplatin and carboplatin and
comparatively high levels of resistance to ormaplatin (Perez
et al., 1991). The drug exposure time may need to be
considered when examining resistance to platinum complexes
as our platinum-resistant cell line E5 could be classified in
either category depending on the duration of drug exposure.
For the 1 h exposure ormaplatin was preincubated in RPMI
medium with 10% fetal bovine serum before addition to cells.
Under these conditions HPLC analysis revealed that over
90% of the ormaplatin was reduced to PtCl2(trans-dach)Ormaplatin resistance
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Table I Sensitivity of cell lines to various platinum-containing analogues [IC50 (gM) ±s.e.]
Drugs Rl E8 E5
Four day exposure
Cisplatin 0.73+0.lOa (1) 9.43+0.02 (12.9)b 18.27+ 1.02 (24.9)
Carboplatin 3.89+0.30 (1) 82.08+ 1.30 (21.1) 152.54± 1.70 (39.2)
Ormaplatin (d,1) 0.19+0.02 (1) 0.75+0.02 (4.0) 1.57+0.10 (8.3)
Ormaplatin (d) 0.18±0.01 (1) 0.90+0.02 (5) 1.94+0.07 (10.8)
Ormaplatin (1) 0. 41+0.01 (1) 2.26+0.01 (5.51) 4.48+0.01 (11.9)
PtCl2 (trans-dach) 0.15±0.01 (1) 0.60+0.07 (4.0) 1.36+0.06 (9.1)
One hour exposure
Cisplatin 19.47+1.00 (1) 97.03+8.50 (5.0) 234.70+9.7 (12.5)
Ormaplatin (d,I)c 0.86+0.05 (1) 5.22+0.36 (6.1) 46.64+4.0 (54.2)
Ormaplatin (d,I)PBSd 13.82± 2.58 (1) 47.60±6.10 (3.4) 96.90± 11.1 (7.0)
aIC50valuesweredetermined byMTT assayandrepresent themeans± s.e. of2-4separateexperiments eachdonein
quadruplicate. bFigures in parentheses represent the fold resistance relative to RI 1. COrmaplatin was incubated in
RPMI + 10% fetal bovineserumfor 1 hat 37°C beforeadditionto cells. dCellsexposed to ormaplatininPBS +glucose.
(data not shown). When ormaplatin was tested in PBS
instead of RPMI medium supplemented with 10% fetal
bovine serum, in order to minimise reduction of ormaplatin,
the IC50s were considerably higher particularly in Rl. and
E8. While the cisplatin-resistant cells were still cross-resistant
to ormaplatin in PBS, the degree of cross-resistance was less
than that observed in RPMI medium with serum.
Drug accumulation
In preliminary experiments it was noted that when Rl.I and
E5 cells were exposed to radiolabelled ormaplatin the
intracellular accumulation of radiolabelled drug was
decreased in RPMI medium without serum compared with
PBS. Furthermore, there was less drug accumulated in the
resistant cells compared with the parental cells when
incubated in medium but this was not the case when the
incubation took place in PBS. In PBS there was in fact a
trend for increased drug accumulation in the resistant cell
lines (Figure 2). This was confirmed by experiments in which
accumulation of ormaplatin in PBS over 5 min revealed a
28-66% increase in E5 in the 1-10 Mm concentration range
(data not shown).
In order to determine which component of RPMI medium
modulated the accumulation of ormaplatin, accumulation
was measured in different PBS buffers each supplemented
with a component of RPMI medium. Only the addition of
the amino acid cystine resulted in decreased accumulation of
radiolabelled drug similar to that seen with complete RPMI
medium. When cells were exposed to ormaplatin the
accumulation of radiolabelled drug in the presence of PBS
supplemented with cystine was similar to the accumulation of
PtCl2(trans-dach), with an inverse rank correlation with the
level of resistance (Figure 2). This raised the possibility that
in the presence of cystine, ormaplatin was being converted to
PtCl2(trans-dach), although previous work had suggested that
cystine was not one of the components of RPMI medium
which could convert ormaplatin to PtCl2(trans-dach)
(Gibbons et al., 1989).
Reduction of ormaplatin in transport buffer
In order to determine the fate of ormaplatin in different
transport buffers HPLC analysis was performed. The
percentage of ormaplatin remaining at 30 min was calculated
(Table II). There was little conversion to PtCl2(trans-dach) in
PBS and glucose but in the presence of cells there was an
unexpected 40-50% reduction. The addition of cystine
resulted in a 40% decrease and in the presence of RI.1 and
E5 cells there was a 64% and 91% decrease respectively. The
effect of cystine was also demonstrated by the fact that in
RPMI medium the reduction of ormaplatin was approxi-
mately 20% greater than in RPMI medium without cystine.
The most extensive reduction of ormaplatin in the absence of
NH2 CI
ClPt
2
NH2 CI
PtCI2(trans-dach)
Figure 1 Structures of ormaplatin and dichloro(D,L-trans)1,2-
diaminocyclohexaneplatinum(II) [PtCl2(trans-dach)].
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Figure 2 Accumulation of ormaplatin and PtCl2(trans-dach) in
Ri.1 and its cisplatin-resistant variants E8 and E5. Thirtymin
accumulation of 2.5Mm ormaplatin (LI, in PBS+glucose; _,
in PBS+glucose+cystine) and 2.5Mm PtCl2(trans-dach) (M, in
PBS +glucose). Results are the means+s.d. of three experiments.
cells took place in RMPI medium supplemented with 10%
fetal bovine serum.
Extracellular thiol concentration
As the reduction of ormaplatin in PBS and cystine was
significantly greater in the presence of E5 cells than Rl.1 cells
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Table II Reduction of ormaplatin to PtCl2 (trans-dach) in different
transport buffers as determined by reversed-phase HPLC analysis
Percentage of ormaplatin
remaining after 30 min
incubation
Transport buffer (mean ±s.d.; n=3)
PBS +glucose 93.9 ± 6.9
PBS+glucose, incubating R1.1 cells 58.6±4.9
PBS +glucose, incubating E5 cells 51.7 ± 7.9
PBS+glucose+cystine 61.0± 13.6
PBS+glucose+cystine, incubating RI.1 33.8 ± 3.3
PBS +glucose +cystine incubating E5 9.3 i4.0
RPMI medium 49.3 ± 5.2
RPMI medium without cystine 68.8 ±7.4
RPMI medium + 10% FBS 32.0 ± 5.2
we sought to determine whether there was a difference in the
formation of extracellular thiols that could account for it.
Thiols in media supplemented with serum and in rat plasma
have previously been found to be important reducing agents
for the conversion of ormaplatin to PtCl2(trans-dach)
(Gibbons et al., 1989; Chaney et al., 1990). However, the
role of thiols which have effluxed out of cells has not been
previously determined. The extracellular thiol concentration
was 1.4+0.3 JgM following incubation of Ri.1 in PBS and
2.4+1.5 ,UM following incubation of the cells in PBS
containing cystine. Following incubation of E5 cells the
respective values were 2.1+0.8 ,UM in PBS and 39.7+6.5 JiM
in PBS containing cystine. The marked increase in
extracellular thiol formation in the presence of E5 compared
with Rl.1 when cystine was present would therefore explain
the more rapid reduction of ormaplatin in the presence of E5
cells.
Transport of PtC'l(trans-dach)
As accumulation of PtCl2(trans-dach) or ormaplatin under
conditions in which it was predominantly converted to
PtCl2(trans-dach), was reduced in the platinum-resistant cells
the transport of PtCl2(trans-dach) was studied in more detail.
The accumulation of 2.5 JIM PtCl2(trans-dach) in E5 was 37-
53% less than in Ri.1 over the first hour (Figure 3). From
2.5 up to 100 JgM there is a 40-50% reduction in the 5 min
accumulation of PtCl2(trans-dach) in E5 (Figure 4). The
increase in accumulation with increasing concentration is
linear in RI.1. In E5 there is some deviation from linearity at
100 yiM but the low solubility of this compound prevented
testing at higher concentrations to determine whether there
really was saturation. Although these studies were done over
a relatively short time interval (5 min), they do not
necessarily represent zero-trans conditions which are ideally
required to measure drug influx. However, efflux studies
demonstrated that there was no increase in efflux in E5 that
could account for the lower drug accumulation in these cells
(Figure 5). Hence these results are more consistent with
decreased influx rather than increased efflux.
Effect of temperature, sodium, metabolic inhibitors and
platinum-containing analogues on the accumulation of
PtCl2(trans-dach)
The 5 min accumulation of 2.5 JIM [3H]PtCl2(trans-dach) was
measured under various conditions and the results expressed
as a percentage of the accumulation of the drug in Ri.L1 or
E5 at 37°C (Table III). The accumulation was temperature
dependent with an 80-84% decrease at 4°C. The absence of
sodium in the transport buffer resulted in only a very minor
decrease in accumulation. The effect of metabolic inhibitors
was most intriguing. Both sodium azide and dinitrophenol
resulted in a 65-70% increase in drug accumulation in RI.1.
In E5 the effect was even more dramatic with a 113%
increase with sodium azide and a 307% increase with
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Figure 3 Accumulation of 2.5,M PtCl2(trans-dach) over 60min
in R1.1 (-a-) and E5 (- -0- -). Points are the means+s.d. of
three experiments. When the s.d. was less than the symbol size,
error bars were omitted.
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Figure 4 Accumulation of PtCl2(trans-dach) from 2.5,UM up to
l00uM in R1.L (- -) and E5 (- -0- -). Accumulation at 5min
was measured. Inset shows accumulation in lower concentration
range. Points are the means+s.d. of three experiments. When the
s.d. was less than the symbol size, error bars were omitted.
dinitrophenol. In order to exclude a generalised increase in
permeability with these inhibitors that could account for the
increased accumulation, the permeability to trypan blue was
assessed. We found no difference in the permeability of Ri.
or E5 to trypan blue in the presence or absence of the
inhibitors after 10 or 30 min incubations. One explanation
for such an increase in accumulation under conditions of
energy depletion would be the presence of an energy-
dependent efflux pump. We measured the efflux of drug in
the presence or absence of sodium azide. At 5 min the
percentage of drug remaining intracellularly in the absence of
sodium azide was 83.7%+12.7 in RII and 87.2%+9.1 in
E5. In the presence of 10 mM sodium azide the corresponding
values were 88.8%+8.0 in RII and 75.7%+7.2 in E5. The
differences in efflux in the presence or absence of sodium
azide were not significant and there was certainly no trend for
a decrease in efflux in the presence of azide.
A 40-fold excess of unlabelled PtCl2(trans-dach) resulted in
a 40% decrease in the accumulation of radiolabelled drug,
which would not be expected if the entry into cells of
PtCl2(trans-dach) was by passive diffusion alone. Neither
cisplatin nor transplatin had any effect on PtCl2(trans-dach)
n ElOrmaplatin resistance
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accumulation. Interestingly, excess ormaplatin appeared to
stimulate the accumulation of PtCl2(trans-dach), with a more
pronounced effect in E5. Accumulation of PtCl2(trans-dach)
after preincubation with excess ormaplatin was not increased.
Discussion
Our studies have demonstrated that the E8 and E5 cisplatin-
resistant cell lines are cross-resistant to ormaplatin and
PtCl2(trans-dach). Furthermore, these cell lines which have
previously been demonstrated to have decreased cisplatin
accumulation, also exhibit energy-dependent decreased
accumulation of PtCl2(trans-dach), a drug to which they
have not been previously exposed. Our cytotoxicity, HPLC
and drug accumulation data are consistent with ormaplatin
being a prodrug for PtCl2(trans-dach) as has been proposed
by other investigators (Anderson et al., 1986; Gibbons et al.,
1989).
The cytotoxicity of ormaplatin in PBS was much less than
in RPMI medium with 10% fetal bovine serum. Our HPLC
analysis demonstrated that even in PBS in the presence of
cells there is significant reduction of ormaplatin. The
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Figure 5 Efflux of PtCl2(trans-dach) from Ri.1 (-a-) and E5
(- -0- -). R1.1 was loaded with 2.5 IIM [3H]PtCl2(trans-dach) and
E5 with a 3.75,M, each for 15min. Release of drug into drug-free
buffer was measured over 30min. Points are the means+s.d. of
three experiments. When the s.d. was less than the symbol size,
error bars were omitted.
cytotoxicity that is seen in PBS could be largely owing to
the PtCl2(trans-dach) that was formed in the extracellular
buffer, and it is less than in media with serum as there is less
PtCl2(trans-dach) formed in PBS. These results suggest that
the ormaplatin that crosses the plasma membrane without
prior reduction is less cytotoxic than ormaplatin which is
reduced to PtCl2(trans-dach) extracellularly. In fact ormapla-
tin that is not reduced extracellularly may not result in any
significant cytotoxicity, at least in the cell lines we have
examined. These findings are consistent with the findings of
Chaney and colleagues who demonstrated in an L1210 cell
line that most of the ormaplatin was not converted to
PtCl2(trans-dach) intracellularly but to two other transforma-
tion products that were not reactive with DNA (Chaney et
al., 1991). Our results differ from the report by Eastman in
an L1210 cell line where he found increased ormaplatin
cytotoxicity in Hanks' balanced salt solution, and postulated
that ormaplatin could be reduced to PtCl2(trans-dach)
intracellularly (Eastman, 1987). In another study using the
same L1210 cell lines the cytotoxicity of ormaplatin in
Hanks' balanced salt solution was increased by the addition
of glutathione which increased extracellular conversion to
PtCl2(trans-dach) (Kido et al., 1994). All these studies
support the hypothesis that ormaplatin requires reduction
to PtCl2(trans-dach) for biological activity.
Our HPLC results emphasise the importance of determin-
ing the amount of ormaplatin reduction that occurs under the
conditions used in cytotoxicity or transport studies. It had
not been previously appreciated that there would be an
increase in the reduction of ormaplatin in the presence of
cells, nor that cystine in the media may contribute to this
reduction of ormaplatin. The increased formation of thiols in
the extracellular buffer in the presence of cystine is probably
due to the uptake of cystine by the cells, its rapid conversion
to cysteine and subsequent efflux out of the cells, as has been
demonstrated in skin fibroblasts (Bannai and Ishii, 1980). The
striking difference in the concentration of extracellular thiols
between sensitive and resistant cells can be at least partly
explained by the fact that there is increased cystine uptake in
the resistant cells (D Rischin and V Ling, manuscript in
preparation). Previous reports of the percentage of ormapla-
tin remaining after a 30 min incubation in RPMI medium
with 15% fetal bovine serum have ranged from 5% to over
80% (Bhuyan et al., 1991; Gibbons et al., 1989). Our result of
32% was obtained with a lower percentage of fetal bovine
serum, 10%. These variable results may be caused by
different sources of serum.
Similar to our previous findings with cisplatin (Kawai et
al., 1990) there was an inverse rank correlation between the
level of ormaplatin or PtCl2(trans-dach) resistance and the
accumulation of PtCl2(trans-dach), suggesting that decreased
Table Ill Effect of temperature, sodium, metabolic inhibitors and other platinum-containing
analogues on the accumulation of 2.5fLM [3H]PtCl2 (trans-dach)
Percentage of control accumulation+s.d. (n =3 -6)
Conditions R1I ES
40C 16.0±8.9 20.7+2.5
Sodium-free buffera 93.5 ± 2.5 89.0± 8.2
Sodium azide (10mM ,b 169.2 ± 33.4 212.7± 21
Dinitrophenol (1 mM) 165.7 +26.8 406.7± 86.1
PtCl2 (trans-dach) (100yLM)C 62.0+4.1 59.0+ 12.5
Cisplatin (100uM)c 103.0+6.0 NTd
Transplatin (100PM)c 97.4+ 7.5 NT
Ormaplatin (100,IM)C 125.3+ 3.1 164.7+ 20.0
Preincubation ormaplatin (100pM)e 113.7 ± 22.3 105.0+ 5.3
Five minute accumulation of 2.5jUM [3H]PtCl2 (trans-dach) was measured under various conditions.
Results are expressed as a percentage ofthe accumulation of2.5gLM [3H]PtC12 (trans-dach) in R 1I or E5
at 37°C in PBS without any added drugs. aSodium was replaced by choline. bCells were preincubated
with inhibitor for 5min, then exposed to drug with inhibitor for 5min. cCo-incubation of [3H]PtC12
(trans-dach) with 40-fold excess ofunlabelled drug. dNT, not tested. ePreincubation for 10min then cells
exposed to 2.5,UM PtCl2 (trans-dach) alone.
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accumulation may play a role in the cross-resistance to these
drugs in the platinum-resistant cell lines. However, it cannot
fully explain the dramatic increase in ormaplatin resistance
between E8 and E5 seen in the 1 h exposure assays.
Ormaplatin accumulation was actually increased in the
resistant cells which provides further indirect support for
the notion that PtCl2(trans-dach) rather than ormaplatin
accumulation contributes to ormaplatin sensitivity.
Studies in L1210 models have demonstrated that the
cisplatin-resistant variants have only minor levels of cross-
resistance to ormaplatin or PtCl2(trans-dach) (Richon et al.,
1987; Kraker and Moore, 1988; Goddard et al., 1991;
Nicolson et al., 1992), which in turn is associated with only
slight decreases in the accumulation of PtCl2(trans-dach)
(Richon et al., 1987; Nicholson et al., 1992; Gibbons et al.,
1990). However, other cisplatin-resistant variants have more
significant levels of cross-resistance to ormaplatin (Teicher et
al., 1991; Bhuyan et al., 1991; Kelland et al., 1992). L1210
variants selected in PtCl2(trans-dach) or ormaplatin have
demonstrated significantly decreased accumulation of
PtCl2trans-dach) (Richon et al., 1987; Nicolson et al., 1992;
Gibbons et al., 1990). The mechanism of decreased
accumulation of PtCl2(trans-dach) has not been studied
extensively. One recent study found no difference in efflux
(Nicolson et al., 1992). We also found that there was no
apparent increase in efflux in the resistant cells. The decrease
in accumulation was detectable at low concentrations and
over short time intervals (2-5 min). Most interestingly,
inhibition of energy metabolism resulted in increased
accumulation with a more marked effect in the resistant
cells. There did not appear to be any decrease in efflux in the
presence of sodium azide, as would be expected if there was
an energy-dependent efflux transporter involved. Our results
would appear to favour decreased influx as the mechanism of
decreased accumulation. One possibility is that there is an
energy-dependent restriction to PtCl2(trans-dach) influx which
is greater in the resistant cells, so that in the absence of
energy the accumulation between the sensitive and the
resistant cells is decreased or abolished. However, as
increased accumulation following inhibition of energy
metabolism is more characteristic of an efflux transporter,
the possibility of increased efflux in the resistant cells cannot
be excluded despite the fact that we could not demonstrate
any such increase. It is interesting to note that in some
multidrug-resistant cell lines that overexpress P-glycoprotein
reduced influx has been reported (Sirotnak et al., 1986; Ramu
et al., 1989). It has been postulated that the influx of drug
can be altered by the presence of an efflux pump such as P-
glycoprotein under certain circumstances (Demant et al.,
1990). The effect of energy depletion on PtCl2(trans-dach)
transport has not been previously reported. In our cell lines
neither sodium azide nor dinitrophenol altered cisplatin
accumulation (data not shown). Conflicting results have
been reported in studies examining the effect of energy
depletion on cisplatin accumulation in human ovarian
carcinoma cell lines. Andrews et al. (1988) found that a
combination of inhibitors of oxidative phosphorylation and
inhibitors of glycolysis resulted in a decrease in cisplatin
accumulation in both sensitive and resistant cells, while Sharp
et al. (1995) demonstrated an increase in cisplatin accumula-
tion in both sensitive and resistant cells under similar
conditions.
As to whether there is a mediated component to
PtCl2(trans-dach) influx we did not demonstrate saturation
but we were unable to go above 100 gM owing to the low
solubility of PtCl2(trans-dach). The accumulation of
PtCl2(trans-dach) was inhibited by unlabelled drug and was
temperature dependent, features which would be consistent
with mediated transport but in themselves do not establish its
presence. It seems unlikely that the decreased accumulation
of PtCl2(trans-dach) and cisplatin in these resistant cell lines
share a common mechanism, as there was no inhibition of
PtCl2(trans-dach) accumulation by excess cisplatin, and
PtCl2(trans-dach) accumulation but not cisplatin accumula-
tion is energy dependent. Our laboratory has been interested
in identifying plasma membrane proteins that are differen-
tially expressed between cisplatin-sensitive and -resistant cells
hypothesising that such a protein or proteins may play a role
in mediating the decreased accumulation of cisplatin and/or
PtCl2(trans-dach) in the resistant cells. The more marked
effect of metabolic inhibitors on PtCl2(trans-dach) accumula-
tion in resistant cells than sensitive cells would be consistent
with the presence of an energy-dependent transporter with
altered expression in the resistant cells. We have previously
reported the overexpression of a plasma membrane
glycoprotein CPR-200 in the cisplatin-resistant variants of
Rl.1 (Kawai et al., 1990), while others have reported
decreased expression of the membrane protein SQM1 in
platinum-resistant human squamous carcinoma cell lines
(Bernal et al., 1990) and the overexpression of a 36 kDa
plasma membrane protein in a cisplatin-resistant human
ovarian carcinoma cell line (Sharp et al., 1995). It is not
known at the present time whether any of these membrane
proteins have a role in mediating the decreased accumulation
of platinum that is commonly present in cisplatin-resistant
cell lines.
In summary our cisplatin-resistant cell lines are cross-
resistant to ormaplatin and PtCl2(trans-dach) and this is
associated with an energy-dependent decreased accumulation
of PtCl2(trans-dach). Ormaplatin cytotoxicity appears to
result primarily from extracellular conversion to PtCl2(trans-
dach), since ormaplatin cytotoxicity was decreased under
conditions where extracellular conversion to PtCl2(trans-dach)
was minimised. In plasma rapid conversion of ormaplatin to
PtCl2(trans-dach) occurs but when ormaplatin is given by
other routes, e.g. intraperitoneally (Plaxe et al., 1993), the
rate of extracellular conversion to PtCl2(trans-dach) may
determine the intracellular levels of biologically active drug.
Abbreviations
cisplatin, cis-diamminedichloroplatinum(II); ormaplatin, tetra-
chloro(D,L-trans)-1,2-diaminocyclohexaneplatinum(II), also called
tetraplatin; PtCl2(trans-dach), dichloro(D,L-trans)-1,2-diaminocy-
clohexaneplatinum(II); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide; PBS, phosphate-buffered saline;
HPLC, high-pressure liquid chromatography.
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